This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation.The study consists of two stages I, Stage I ：explores the combination dose and the second phase; Stage II ：patients were randomized 1:1 to receive either the experimental regimen DN022150 plus AG or the control regimen AG alone.
Voluntarily signed informed consent form
Age 18-75 years (inclusive), male or female, at the time of signing informed consent
Life expectancy ≥ 12 weeks
Subjects with confirmed KRAS G12D who have not received prior systemic antineoplastic therapy for advanced or metastatic pancreatic cancer
Progression or other malignancy requiring treatment within 5 years prior to enrollment
Prior targeted therapy for KRAS G12D
With central nervous system metastasis
Uncontrolled fluid accumulation